Global Market Study on Uveitis Treatment: Acceptance for Local Steroid Implants on a Visible Rise


Uveitis Treatment  Market
  • Published On : Sep-2019 |
  • Pages : 163 Pages |
  • Format : Uveitis Treatment  Market Uveitis Treatment  Market Uveitis Treatment  Market Uveitis Treatment  Market

The uveitis treatment landscape has been witnessing significant development because of increasing elderly population, developing pervasiveness of uveitis, and related complications. Besides, introduction of novel biologics, fast-track pipeline drugs, increasing investment in the research, and development for new drug discovery are prominently driving the development of the uveitis treatment market. The global uveitis treatment market size was ~US$ 567 Mn in 2018, which is likely to be increasing at a CAGR of ~6% during the forecasted period of 2019-2029.

Uveitis treatment includes corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. Antibiotics in the uveitis treatment type segment is expected to be the fastest growing segment during the forecast period, owing to rise in autoimmune disorders globally. In terms of revenue, corticosteroids in the uveitis treatment type segment is the largest segment and is expected to keep constant traction during the forecast period, owing to be used as a first line treatment for uveitis. These are used in different formulations from eye drops to sustained release drug formulations.

New route of drug administration to improve its efficiency is another important driver for the uveitis treatment market with advent of intravitreal inserts and biologic agents progressively utilized for uveitis treatment. By improvements in molecular science, more therapeutic approach and methodologies have been applied to control ocular aggravation caused by uveitis, which are relied upon to impact the uveitis treatment market.

global uveitis treatment market

Infection remains the key source of uveitis in developing nations, such as India, and others. Whereas, in developed countries, idiopathic uveitis, an organ-specific immune inflammatory process, has been touted as the prime source of the disease. Infectious uveitis accounts for considerable revenue shares of more than 85% in the market owing to increase in the prevalence of infectious diseases in developing countries. ~57% of the total revenues of uveitis treatment market is accounted by anterior uveitis, followed by posterior uveitis. The prevalence of the former is observed to be higher across all the regions, as indicated by surveys.

R&D Efforts Focusing on Non-steroidal Injectables

Uveitis treatment drugs manufacturers are concentrating on developing technologically advanced products as well as novel drug formulations that can reduce uveitis and allow ophthalmologist to offer improve ophthalmic treatment and patient care. Major players in uveitis treatment are focusing on introducing steroid implants, which is proving out to be significantly accepted for drug delivery in case of noninfectious posterior uveitis.

Moreover, key players are increasingly inclined towards developing drug formulations, which act as an adjuvant therapy for uveitis treatment. Adjuvant immunosuppressing agents in uveitis treatment are frequently been used these days, which has shown better results in the past. Companies are investing in research and development activities to develop non-steroidal injectable for uveitis treatment as corticosteroids have a potential side effects in long term use.

Limited First Line Drugs Continue to Obstruct Market Growth

Incidences of adverse effects related to uveitis treatment medication such as irritation, watery eyes, and others are increasing among patients. These factors are becoming major challenges for healthcare professionals and institutions as few studies regarding the efficacy of agents used for treating uveitis are present. Moderate prevalence and very limited first line drugs are other challenges for the growth of the uveitis treatment market.

Moreover, eye care products for uveitis treatment need unique manufacturing process for making products appropriately aligned with GMP regulations for sterile products. Since formulations are prone to get affected by pathogens present in the environment, they are formulated under highly protected area, which poses a major challenge facing manufacturers to fulfil the criteria as mentioned in GMP and other regulatory guidelines. Additionally, poor primary medicinal services infrastructure, absence of awareness about eye disorders, and absence of medical coverage in developing nations are additionally discouraging the uveitis treatment market.

North America’s Primacy in Uveitis Treatment Market to Prevail

North America will continue to be the prominent regional market for uveitis treatment due to rising burden of increasing prevalence of infectious uveitis and growing elderly population. North America holds significant market share in the uveitis treatment market with ~33% of total revenue and is expected to grow with a CAGR 6.0% in the forecasted period. On the other hand, Europe represents second most lucrative region in the uveitis treatment market and is expected to grow 5.9% in the forecasted period with ~27% of market share due to growing R&D initiatives as well as rising healthcare expenditure in this region.

Leading Market Players Yearning for Extended Footprint in Global Market

Allergan. Inc., Novartis AG; Santen Pharmaceutical Co., Ltd and AbbVie Inc.; are among the leading market players in the uveitis treatment market. Other manufactures, such as Eyegate Pharmaceuticals and Alimera Science Inc, are increasing their footprint in developed and emerging economies globally. They continue to dominate the market landscape of uveitis treatment due to investment in research and development, product diversification, and strategic partnerships and acquisitions in order to enhance product and customer base.

In Sept 2019, Alimera launched ILUVIEN in Germany, is the second country in Europe, in which ILUVIEN is now commercially available to be prescribed to patients suffering from Non Infectious Posterior Uveitis (NIPU). In Feb 2019, Alimera Science received approval for ILUVIEN from Ministry of Health in Lebanon. MEAgate is the ILUVIEN distributor for Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, UAE, and Yemen. In Feb 2018, DEXYCU (dexamethasone intraocular suspension) 9% of EyePoint Pharmaceuticals was approved by U.S. Food and Drug Administration (FDA). 

Analysts’ Viewpoint

A comprehensive view of the uveitis treatment market has led our analysts to conclude that, the market is growing at an impressive rate, with North America and Europe holding a large chunk of the global uveitis treatment market and its treatment, cause, and diseases type. The increasing uveitis treatment market due to increase in the number of patients suffering from uveitis and other eye disorders and increase in the prevalence of infectious uveitis in developing countries are spurring the growth of the uveitis treatment market. Strong financial position and new product development of key market players will also give impetus to the uveitis treatment market.

Companies with research and development capabilities and technological prowess will gather momentum and profitability in the uveitis treatment market. Leading players who are leveraging technology and approved novel products will continue to grow exponentially and have a vast market revenue share. 

Persistence Market Research (PMR) recently published a market study on the global market for Uveitis treatment. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the uveitis treatment market structure. The market study presents exclusive information about how the uveitis treatment market will grow during the forecast period of 2019-2029.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. Other information includes pipeline analysis which comprises of detail information about the ongoing clinical trials across all regions. There other information contains total number of molecules, which are under clinical trials for uveitis treatment. This information helps in deep understanding of the future scope of different drugs available for uveitis treatment by drug manufacturers, researchers and medical practitioners.

The other information contains incidence, distribution, possible control of diseases and other factors relating to the health due to uveitis diseases. The other information contains market size in value analysis, which includes year wise growth of uveitis treatment during the forecasted period. This information can help readers understand the quantitative growth prospects of the uveitis treatment market during the forecast period. The study is relevant for drug manufacturers, distributors, wholesalers and regulatory experts and can help them in developing appropriate strategies to grow in the market.

The study also includes statistics as well as facts related to macro as well as microeconomic factors that are impacting developments in the market. It also offers actionable insights based on future trends in the uveitis treatment market. Furthermore, new entrants in the uveitis treatment market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Key Segments of the Uveitis Treatment Market

PMR’s study on the uveitis treatment market offers information divided into five important segments - treatment type, diseases type, cause, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Treatment

Diseases

Cause

Distribution Channel

Region

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antivirals
  • Antifungals
  • Analgesic
  • Antibiotics
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
  • Infectious Uveitis
  • Non-infectious Uveitis
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Questions Answered in PMR’s Uveitis Treatment Market Report

  • Which regions will continue to remain the most profitable regional markets for uveitis treatment market players?
  • Which factors will induce a change in the demand for uveitis treatment during the assessment period?
  • How will changing trends impact the uveitis treatment market?
  • How can market players capture the low-hanging opportunities in the uveitis treatment market in developed regions?
  • Which companies are leading the uveitis treatment market?
  • What are the winning strategies of stakeholders in the uveitis treatment market to upscale their position in this landscape?

Uveitis Treatment Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the uveitis treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analyst ensure accuracy and reliability of conclusions.

Secondary resources referred to analyst during market study include statistics from government healthcare organizations, medicines journals, research journals, press release, annual reports, white papers, directories and databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the uveitis treatment market, and makes PMR’s projection on the growth prospects of the uveitis treatment market more accurate and reliable.

Companies covered in Uveitis Treatment Market Report

Company Profiles:

  • Allergan, Inc.
  • Novartis AG
  • Bausch Health Inc.
  • AbbVie Inc.
  • Eyegate Pharmaceuticals, Inc.
  • Alimera Science Inc.
  • EyePoint Pharmaceuticals
  • Santen Pharmaceuticals

 

Back To Top